Senores Pharmaceuticals Ltd.
1,202.50
INR
-20.80
(-1.70%)
ISIN
INE0RB801010
Return %
Stock
S&P 500
1Y
60.21
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Swapnil Jatinbhai Shah
- Full Time Employees
- 368
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- South Tower Ahmedabad GU India 380054
- IPO Date
- Dec 30, 2024
- Website
- senorespharma.com
- Similar Companies
- Business
- Senores Pharmaceuticals Ltd. (SENORES.NS) is a global research-driven pharmaceutical company engaged in developing and manufacturing complex generics, critical care injectables, and active pharmaceutical ingredients (APIs) predominantly for regulated markets including the US, Canada, and the UK, as well as emerging markets across 43 to 49 countries; its core products encompass tablets, capsules, ampoules, liquid vials, dry powder vials, oral liquids, and other dosage forms across various therapeutic areas, with a portfolio of over 205 products including 27 ANDAs and 21 CMO/CDMO commercial products approved for US distribution, alongside contract research services, analytical method development, ANDA filings, IP formulations, process technology, and novel drug delivery systems. Founded in 2017 and headquartered at 1101 to 1103, 11th Floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat 380058, India, the company operates four manufacturing facilities comprising one USFDA-approved plant in Atlanta, USA, which is also DEA/BAA compliant; a WHO-GMP approved formulation facility in Chhatral, India; and two API plants near Ahmedabad in Chhatral and Naroda, supported by three R&D sites. Senores Pharmaceuticals maintains a wholly-owned US subsidiary, Senores Pharmaceuticals Inc., and has expanded through strategic acquisitions including Ratnagene Lifescience Private Limited in 2021 for API capabilities; in March 2025, it acquired 14 ANDAs from Dr. Reddy’s Laboratories—13 USFDA-approved and one pending—with an addressable US market opportunity of approximately USD 421 million (IQVIA MAT Dec 2024) to USD 1.13 billion (Symphony MAT Sep 2024)—funded by IPO proceeds; recent developments further include a USD 2 million rights issue investment in its US unit in September 2025, Q2 FY2026 net profit surge to Rs 6.43 crore, and appointment of Manohar Lalge as Senior Management Personnel in November 2025.